EU/3/10/832

About

On 23 February 2011, orphan designation (EU/3/10/832) granted by the European Commission to Apotex Europe B.V., the Netherlands, for deferiprone for the treatment of sickle cell disease.

The sponsorship was transferred to Apotex B.V, Netherlands, in May 2019. The sponsor’s address was updated in January 2020.

Key facts

Active substance
Deferiprone
Disease / condition
Treatment of sickle cell disease
Date of first decision
23/02/2011
Outcome
Positive
EU designation number
EU/3/10/832

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Apotex B.V.
Locatellikade 1
1076 AZ Amsterdam
Netherlands
E-mail: Info_apotexbv@apotex.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating